Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma

被引:58
作者
Jain, Lokesh [1 ,2 ]
Gardner, Erin R. [3 ]
Venitz, Juergen [2 ]
Dahut, William [4 ]
Figg, William D. [1 ]
机构
[1] NCI, Clin Pharmacol Program, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Virginia Commonwealth Univ, Sch Pharm, Dept Pharmaceut, Richmond, VA 23298 USA
[3] NCI Frederick, SAIC Frederick Inc, Clin Pharmacol Program, Ft Detrick, MD 21702 USA
[4] NCI, Med Oncol Clin Res Unit, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
BAY43-9006; kinase inhibitor;
D O I
10.1016/j.jpba.2007.10.027
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A rapid and sensitive liquid chromatography/tandem mass spectrometric (LC/MS/MS) assay was developed for the quantitative determination of sorafenib in human plasma. Sample pretreatment involved simple protein precipitation by the addition of 0.5 mL acetonitrile, containing internal standard ([H-2(3), N-15] sorafenib), to 50 mu L of plasma sample volume. Separation was achieved on a Waters SymmetryShield RP8 (2.1 mm x 50 mm, 3.5 mu m) column at room temperature using an isocratic elution method with acetonitrile/0.1% formic acid in water: 65/35 (v/v) at a flow rate of 0.25 mL/min. Detection was per-formed using electrospray ionization in positive ion multiple reaction monitoring (MRM) mode by monitoring the ion transitions from m/z 464.9 --> 252.0 (sorafenib) and m/z 469.0 --> 259.0 (internal standard). Calibration curves were linear in the concentration range of 5-2000 ng/mL. The accuracy and precision values, calculated from three different sets of quality control samples analyzed in quintuplicate on six different days, ranged from 92.86% to 99.88% and from 1.19% to 4.53%, respectively. (C)- 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:362 / 367
页数:6
相关论文
共 7 条
[1]   Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry [J].
Lakhani, NJ ;
Lepper, ER ;
Sparreboom, A ;
Dahut, WL ;
Venitz, J ;
Figg, WD .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2005, 19 (09) :1176-1182
[2]   Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 [J].
Liu, Li ;
Cao, Yichen ;
Chen, Charles ;
Zhang, Xiaomei ;
McNabola, Angela ;
Wilkie, Dean ;
Wilhelm, Scott ;
Lynch, Mark ;
Carter, Christopher .
CANCER RESEARCH, 2006, 66 (24) :11851-11858
[3]   Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors [J].
Strumberg, D ;
Richly, H ;
Hilger, RA ;
Schleucher, N ;
Korfee, S ;
Tewes, M ;
Faghih, M ;
Brendel, E ;
Voliotis, D ;
Haase, CG ;
Schwartz, B ;
Awada, A ;
Voigtmann, R ;
Scheulen, ME ;
Seeber, S .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :965-972
[4]   Discovery and development of sorafenib: a multikinase inhibitor for treating cancer [J].
Wilhelm, Scott ;
Carter, Christopher ;
Lynch, Mark ;
Lowinger, Timothy ;
Dumas, Jacques ;
Smith, Roger A. ;
Schwartz, Brian ;
Simantov, Ronit ;
Kelley, Susan .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (10) :835-844
[5]   The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 [J].
Yu, CR ;
Bruzek, LM ;
Meng, XW ;
Gores, GJ ;
Carter, CA ;
Kaufmann, SH ;
Adjei, AA .
ONCOGENE, 2005, 24 (46) :6861-6869
[6]  
ZHAO M, 2006, J CHROMATOGR B
[7]  
GUIDELINES IND BIOAN